Viloxazine hydrochloride - Supernus Pharmaceuticals
Alternative Names: QELBREE; SPN 809; SPN 812; SPN-812 ER; SPN-812V; Viloxazine extended-release - Supernus Pharmaceuticals; Viloxazine hydrochloride extended release - Supernus PharmaceuticalsLatest Information Update: 14 May 2024
At a glance
- Originator Rune Healthcare Limited
- Developer Supernus Pharmaceuticals
- Class Antidepressants; Behavioural disorder therapies; Ethers; Morpholines; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
- Discontinued Depressive disorders
Most Recent Events
- 07 May 2024 M8 Pharmaceuticals in-licenses Viloxazine hydrochloride from Supernus to seek regulatory approval and commercialize in Latin America
- 19 Dec 2023 Knight Therapeutics obtains exclusive rights to obtain regulatory approval and commercialize Viloxazine hydrochloride in Canada
- 19 Dec 2023 Knight Therapeutics announces intention to obtain regulatory approval for Attention-deficit hyperactivity disorder in Canada